activity and autoantibody levels, only age added statistically significantly to the prediction (p<0.001). Conclusions: There was indication for preventive intervention in more than half of our patients. Age is a determinant factor that increases CV risk in RA patients independently from disease-specific factors. Treatment to lipid targets is essential to reduce their risk of CV morbidity and mortality (3) . A prospective study evaluating treatment success rate is needed to further evaluate the intervention of the clinic. References: [1] Background: Patients with rheumatoid arthritis (RA) have an increased risk of developing comorbid conditions which are associated to increased mortality, hospital admissions, higher costs of care and inability to work (1, 2) . Objectives: To evaluate the prevalence of comorbidities in a Mexican mestizo population of RA patients. Methods: We performed a cross-sectional study in which RA patients who were admitted to our outpatient clinic between August 2014 and December 2016 were consecutively enrolled. We collected data regarding demographics, disease characteristics (activity, severity, treatment), comorbidities (cardiovascular, infections, cancer, and osteoporosis), and performed blood tests at the time of the patient's visit to the clinic. Results: We analyzed 225 patients. Their characteristics are shown in Table 1 . Age, 55.7±8.3 years (mean ± SD); disease duration, 9.5 (4 -15.5) (median (IQR)); female gender, 93.7%; Disease Activity Score using 28 joints-C-reactive protein (DAS28-CRP), 3 (2 -4) (median (IQR)); past or current methotrexate use, 84.9%; past or current use of any other conventional disease modifying anti-rheumatic drug (cDMARD), 52.4%; past or current use of biological agents, 8%. The most frequently associated diseases were: hypertension, 29.8%; dyslipidemia, 27.1%; osteoporosis, 19.1%; diabetes, 12.4%; hypothyroidism, 6.2%; solid malignancies (excluding basal cell carcinoma), 4.4%. Risk factors were also evaluated, the most prevalent was overweight (BMI ≥25 <30) present in 101 (44.9%) of our patients. A total of 71 (31.6%) had obesity (BMI ≥30). The systematic evaluation of our patients allowed us to detect abnormalities in vital signs, such as elevated blood pressure in 12.4%, and to identify conditions that manifest as laboratory test abnormalities, such as hyperglycemia in 27.1% and hyperlipidemia in 49.8%.
Conclusions:
This study confirms the high prevalence of comorbidities in RA patients. Among our cohort, 63.5% had at least one comorbidity, being those associated with cardiovascular disease the most common. With a systematic assessment (3) including a thorough physical examination, vital signs and laboratory tests, it is possible to detect comorbid conditions that would otherwise remain unrecognized. Background: The prevalence of tuberculosis infection in Russia is much higher than in Western Europe. Therefore, screening for TB infection in patients with RA before therapy with biological agents is of particular importance. At the same time, reliable information on the results of screening are very few. Objectives: Explore the results of the application of different methods of diagnosis of tuberculosis infection in RA patients before and during treatment with biological agents. Methods: We used the data from the Russian register "Observational REgister of arthritis in cLinical practice" (OREL). 1471 RA patients were screened for TB infection before prescribing biologics, of whom 829 patients were exposed to TB infection monitoring on therapy by biologics. The group included 21.1% men, 78.9% women; at the time of initial screening age was 50,0±0,4 years, the duration of the disease 8,5±3,8 yrs, 68,3% RF +, 85.1% anti-CCP +, DAS28-ESR 5,7±1,1, 95,7% used synthetic DMARDs, 60,1% used systemic steroids. We used PPD (Mantoux) test, Diaskin test (intradermal test with tuberculosis recombinant allergens CFP10-ESAT6) and QuantiFERON-TB Gold (QFT) test (in some patients), chest X-ray, chest CT scan (if needed), all the patients were consulted by phthisiatrician. PPD and Diaskin test results were considered positive if the papule was ≥5 mm. Duration of treatment with biologics (anti-TNFs and others) varied widely (2-154 months), making a total of 2552,4 patient-years. Results: At screening, we got 40,3% positive results of PPD test (significantly more in younger patients and patients who did not receive steroids), 16,5% positive results of Diaskin test (with no significant correlations with age and steroids). Positive results matched in 19.9% of cases, negative -in 51.9%. Discordant results in 217 patients were in 92,2% cases related to negative results of Diaskin in PPD-positive persons. Active TB was found after additional examination in 3 (0,2%) patients, inactive TB-related changes were revealed in 124 (8,8%) patients. Positive PPD and Diaskin results, but not QFT, correlated with signs of inactive TB lesions. Positive results of PPD and QFT tests matched in 36.5% of cases, negative -in 18.7%, Diaskin and QFT -in 33,6% and 41,1% of cases resp. As a result of screening, 224 pts were treated by isoniazid or combination of anti-TB drugs before initiation of biologics. On treatment with biologics, 114 (13,7%) pts became PPD-positive and 56 (6,8%) Diaskin positive, active TB was diagnosed in 8 (0,97%) pts.
In carrying out TB screening before prescribing biologics in high-risk population of TB infection it is reasonable to use both PPD and Diaskin tests, and repeat them every 6 months on treatment. Background: US7 score is the ultrasound scoring system for rheumatic arthritis (RA) with the most clinical evidence so far. Several reports accessed its inter-, intra-observer agreement, its specificity, sensitivity and practical possibility compared to more complex scoring systems such as 72-joints scoring systems, which showed it is an convenient tool for clinical use. Objectives: Our goal is to employ US7 to investigate the ultrasonic changes during biological agents plus MTX Treatment in high disease activity refractory RA patients in Yellow people. Methods: All cases were diagnosed as RA fulfilling 2009 ACR/EULAR classification criteria and evaluated as high disease activity for DAS28>5.1 with MTX+HCQ+SASP or MTX+LEF invalid therapy for more than 3 months before baseline. Biological agents including TNF-a antagonist or IL-6 antagonist plus with MTX 10mg qw were then given and ultrasound was performed by 2 observers blinded to physicial examinations and blood tests at 0, 4, 12, 24, 48w. US examination referred to US7 scores by Backhaus et al. DAS28 were employed to assess disease activity. Results: 1) 26 subjects were enrolled in the program up to now. 22 were given TNF-a antagonists and 4 were given IL-6 antagonists. 17 finished 24 weeks follow-up. 1 withdrew for TB infection at 12 week and 1 withdrew for fungi pneumonia at 8 weeks. Mean age of 17 was 44.3±11.8 years old, female-male ratio was 15:2, and disease duration was 71 months. All were RF and ACPA postIve. The above data showed the sum scores found biological agents improved thorough the whole course as Das28 did. Synovitis seemed to be eliminiated faster than tenosynovitis and the repair of bone erosion was the latest event compared to decreased synovitis and tenosynovitis. Conclusions: It is recommended US7 used in clinic for US7 scoring system could reflect more exquisitely than DAS28 in more refined aspects including the changes of tendon, joint, bone at different phrases during biological agent treatment for RA. However, more samples should be included in our study to illuminate above conclusion with sufficient evidence. Background: Co-factors and traditional cardiovascular disease (CVD) risk factors contribute to atherosclerosis in rheumatoid arthritis (RA). Several records since 1953 have reported an increase of up to 4 times the CVD risk and mortality in RA patients. Physicians who evaluate these patients forget to perform or record this assessments in medical records. Since 1948, the Framingham Heart Study became an ambitious project in health research, to identify the general causes of heart disease and stroke, they proposed a new risk estimator of general cardiovascular risk defined as CVD.This estimator was calibrated for Colombia and should be multiplied by a factor of 0.7 Objectives: To describe whether the request and registration of CV risk factors is performed. Also to estimate 10-year risk of CVD in RA patients and to compare the CVD risk among patients receiving or not biological therapy and those with positive and negative anti-cyclic citrullinated peptide (anti-CCP) Methods: We conducted an observational descriptive study of patients who attended a specialized rheumatology clinic in Bogotá, Colombia from 2010 to 2015. Patients with RA were enrolled who had completed at least 5 year of follow-up. The information required to estimate CVD risk was obtained from medical records. Other variables included were biological therapy and test result of anti-CCP. For the calculation of CVD risk, the Framingham estimator was used and adjusted for the Colombian population. Additionally, patients who had 2 or more of these criteria: More than 10 years of evolution of RA, positive rheumatoid factor and/or extra-articular compromise, the risk was adjusted by multiplying by 1.5. Nonparametric statistics (Mann-Whitney U test) was used. Results: We identified 273 eligible patients with RA with mean age 61, 66% women. Only 117 (42.8%) had recorded in their charts all variables to calculate CVD risk. We found that 32% had high blood pressure, 7% type II DM, 11% Obesity and 13% smoking. For the population evaluated, 10-year CVD risk median was 12.42% and for Colombia was 8.69%, adjusting this risk according to the disease in Colombia, increased to 13.03%. When we compare the 10-year CVD risk in anti-CCP positive patients (median: 11.15) and anti-CCP negative (median: 8.22) we did not find difference (p: 0.614). However, we found differences in the 10-year CVD risk median 9.04 vs. 23.25, 10-year CVD risk adjusted to Colombia median 6.32 vs. 16.31 and 10-year CVD risk adjusted to Colombia and RA median 6.81 vs. 13.39 between patients using biological therapy versus patients without receiving respectively (p: <0.001) Conclusions: Only 42.8% of the sample had all CV risk factors requested and registered in the clinical record, so should promote improvement in the health team to increase this. The average 10-year CVD risk in all people with RA was 12.42%, and in patients who met the criteria to be multiplied by the factor 1.5 increased to 13.03%, which means that these patients should be reported this and applied risk prevention guidelines regarding obesity and cholesterol levels. Despite population receiving biologics are younger, they had lower CV risk. We need more research to confirm this results
